Adrenomedullin (AM) exerts profound natriuretic and vasodilatory effects in conscious animals. This newly discovered hormone also acts in the central nervous system to inhibit water drinking and in the pituitary gland to reduce basal and stimulated ACTH release. We investigated whether the natriuretic action of AM in kidney was matched by a central nervous system action to decrease salt intake. Isotonic hypovolemia induced in male rats by pretreatment with polyethylene glycol potently stimulates both water and salt water (0.3 mol/liter NaCl) drinking. Saline drinking was significantly inhibited when AM was administered into the lateral cerebroventricle before the drinking interval. The effect was dose related (dose range, 44 -88 pmol), long lasting (Ͼ5 h), and reversible (resolved at 24 h). When hypovolemic rats were administered antiserum to AM (intracerebroventricular administration) before the drinking interval, a significant 2-fold augmentation of saline drinking was observed. These data suggest that in addition to peripheral actions on cardiovascular and renal function and pituitary actions to inhibit ACTH release, AM may act within the central nervous system to determine fluid and electrolyte balance and, ultimately, blood pressure. (Endocrinology 138: [613][614][615][616] 1997) A DRENOMEDULLIN (AM) is a 50 (rat)-or 52 (human)-amino acid peptide that was originally identified on the basis of its ability to elevate cAMP levels in a platelet bioassay (1). The peptide is produced in multiple tissues, most notably both the endothelial and smooth muscle components of the vasculature, adrenal medulla, anterior pituitary gland, and central nervous system (2-6). AM is one of the most potent hypotensive agents known, exerting most of its vasodilatory effects via generation of nitric oxide (7, 8) . However, the peptide exerts multiple pharmacological effects in a variety of tissues (9, 10), and many of its actions seem related to the homeostatic control of fluid and electrolyte homeostasis particularly and cardiovascular status in general. Indeed, AM is a potent natriuretic agent (8, (11) (12) (13) (14) (15) (16) that acts not only via increasing renal blood flow (in the face of significant peripheral hypotension) but also via direct tubular actions (14). Aldosterone release in response to angiotensin II and potassium is inhibited by AM (17), and both pituitary (18) and central nervous system (19) actions related to fluid and electrolyte homeostasis have been described. The physiological significance of these pharmacological effects has yet to be established; however, it appears that this newly described hormone can act in a coordinated fashion in a number of tissues to contribute to the regulation of renal and cardiovascular function.
A DRENOMEDULLIN (AM) is a 50 (rat)-or 52 (human)-amino acid peptide that was originally identified on the basis of its ability to elevate cAMP levels in a platelet bioassay (1) . The peptide is produced in multiple tissues, most notably both the endothelial and smooth muscle components of the vasculature, adrenal medulla, anterior pituitary gland, and central nervous system (2) (3) (4) (5) (6) . AM is one of the most potent hypotensive agents known, exerting most of its vasodilatory effects via generation of nitric oxide (7, 8) . However, the peptide exerts multiple pharmacological effects in a variety of tissues (9, 10) , and many of its actions seem related to the homeostatic control of fluid and electrolyte homeostasis particularly and cardiovascular status in general. Indeed, AM is a potent natriuretic agent (8, (11) (12) (13) (14) (15) (16) that acts not only via increasing renal blood flow (in the face of significant peripheral hypotension) but also via direct tubular actions (14) . Aldosterone release in response to angiotensin II and potassium is inhibited by AM (17) , and both pituitary (18) and central nervous system (19) actions related to fluid and electrolyte homeostasis have been described. The physiological significance of these pharmacological effects has yet to be established; however, it appears that this newly described hormone can act in a coordinated fashion in a number of tissues to contribute to the regulation of renal and cardiovascular function.
The production of AM (2-4) in the central nervous system and the presence of AM binding in brain extracts (20) have been reported. We have demonstrated that the peptide can act within the central nervous system to inhibit angiotensin II-induced and water deprivation-stimulated water drinking in the rat (19) . We sought in the current experiments to determine whether AM could act in the brain to alter salt appetite, perhaps mirroring in this tissue its natriuretic actions in kidney. Additionally, using specific anti-AM antiserum, we attempted to establish evidence for a physiological role of endogenously produced AM in fluid and electrolyte homeostasis.
Materials and Methods
Adult male rats (250 -300 g; Harlan, Sprague-Dawley, Indianapolis, IN) were housed singly and allowed free access to lab chow, tap water, and salt water (0.3 mol/liter NaCl). With the aid of a stereotaxic device, an indwelling lateral cerebroventricular cannula (17 mm, 23-gauge stainless steel) was implanted with its tip directed into the right lateral ventricle (coordinates relative to the interaural line: ϩ6.2 mm anterior, Ϫ0.8 mm lateral, ϩ7.0 mm vertical) under tribromoethanol anesthesia (Aldrich Chemical Co., Rouses Point, NY; 2.5% in physiological saline, 1 ml/100 g BW, ip). The cannula was sealed with an obturator (25-gauge stainless steel wire) and secured in place by means of stainless steel screws and dental cement. One week after cannula implantation, isotonic hypovolemia was induced by sc injection of 5 ml polyethylene glycol (30%, wt/wt, in 0.15 mol/liter NaCl) as previously described (21) . After 18 h (overnight) of food and fluid restriction, rats received via the lateral ventricular cannula an injection (2 microliters) of either vehicle (0.15 mol/liter NaCl) or vehicle containing synthetic rat AM (Phoenix Pharmaceuticals, Mountain View, CA). Peptides were verified by the vendor to be at least 99% pure by analytic HPLC, amino acid analysis, and mass spectroscopy. The doses of AM chosen for testing (44 and 88 pmol) were those previously demonstrated to significantly inhibit angiotensin II-stimulated and dehydration-induced water drinking, doses that do not significantly alter blood pressure or heart rate when injected into the lateral cerebroventricle of anesthetized rats (19) . In the passive immunoneutralization studies, injections consisted of 2 l normal rabbit serum (NRS) or 2 l rabbit antirat AM antiserum (Phoenix Pharmaceuticals, Mt. View, CA). This antibody (IC 50 in RIA ϭ 32 pg/tube at a titer of 1:24,000) exhibits no cross-reactivity (absence of detection in RIA at 4 log molar excess compared to the AM standard) to human AM, rat or human pro-AM N-20 terminal peptide, amylin, endothelin, rat atrial natriuretic peptide, rat calcitonin gene-related peptide, or oxytocin. Fifteen minutes after the injections, which were conducted in unanesthetized and unrestrained animals, drinking bottles (tap water and 0.3 mol/liter NaCl) were returned to the cages. Intakes were monitored at 30-min intervals for 5 h and again at 24 h. Food was returned to the cages at the end of the initial 5-h sampling period.
Data are expressed as the mean Ϯ sem and were analyzed for between-experimental group differences by ANOVA with subsequent multiple comparison testing (Student-Newman-Keuls procedure). In the case of the passive immunoneutralization, between-group differences were determined by unpaired t test. P Ͻ 0.05 was considered significant. All animal procedures were approved by the University of North Dakota animal care and use committee.
Results
All animals approached the drinking bottles and consumed fluid. There were no significant differences in the amount of tap water consumed at any time point between vehicle-injected controls and rats injected with 44 or 88 pmol AM (Fig. 1) . AM administration significantly inhibited, in a dose-related fashion, saline drinking in response to this isotonic hypovolemic stimulus (Fig. 2) . Compared to vehicleinjected control rats, animals administered 44 pmol AM into the lateral cerebroventricle consumed significantly less 0.3 mol/liter NaCl at 30 and 180 min. At all times during the initial 5-h sampling period, rats in the 88 pmol treatment group consumed significantly less 0.3 mol/liter NaCl than controls. There were no significant differences between AMtreated animals and vehicle-injected controls in terms of cumulative tap water (control, 54.1 Ϯ 2.0 ml; 44 pmol AM, 49.2 Ϯ 3.5; 88 pmol AM, 62.3 Ϯ 2. Passive immunoneutralization of endogenous AM with 2 l rabbit antirat AM antiserum resulted in no significant differences in water intake compared to that of NRS-injected controls (Fig. 3) . However, intake of 0.3 mol/liter NaCl in antiserum-injected rats was significantly greater than that in NRS-injected controls at all times during the 5-h experimental period (Fig. 4) except at the first (30 min) sampling. When the volume of total fluid (tap water and 0.3 mol/liter NaCl) consumed was compared between antiserum and control injected rats, significant augmentations of isotonic hypovolemia-induced drinking was observed in the animals administered anti-AM antibodies (Fig. 5) . No significant differences were observed at 24 h in tap water (NRS, 62.7 Ϯ 1.6 ml; anti-AM, 60.2 Ϯ 1.2), 0.3 mol/liter NaCl (NRS, 25.2 Ϯ 4.7 ml; anti-AM, 26.3 Ϯ 1.2), or cumulative fluid (NRS, 87.4 Ϯ 4.4 ml; anti-AM, 86.6 Ϯ 2.7) consumption.
Discussion
Multiple tissue actions of AM have been demonstrated, many related to cardiovascular and renal function (10) . In addition to its potent hypotensive effect when administered into the vascular tree (1, 7, 13, 22, 23) , the peptide exerts positive inotropic effects in isolated perfused rat hearts (24) and positive inotropic and chronotropic effects in conscious sheep (23, 25) . The hypotensive effect of AM may describe, via reflex activation, the increase in sympathetic function observed in vivo; however, data from experiments in conscious rabbits (26) suggest that AM may, in fact, buffer the sympathetic response to hypotension. On the contrary, recent data suggest direct central nervous system actions of AM to stimulate sympathetic activity (27, 28) .
Vascular effects of AM may in part explain the renal ac- tions of the peptide. In the rat, the natriuretic effect of AM is coincident with an effect to increase renal plasma flow and decrease renal vascular resistance (8, 13, 15) . In anesthetized dogs, intrarenal infusion of AM at doses close to those circulating under normal conditions increased renal blood flow, urine flow, and urinary sodium excretion without affecting blood pressure or heart rate (16). In addition to direct renal actions of AM to control sodium and water excretion, indirect effects may be exerted in the adrenal gland, where AM has been reported to inhibit aldosterone secretion from cultured rat capsular cells (17) . Our laboratory has focused on potential central nervous system and pituitary actions of AM to affect cardiovascular and fluid and electrolyte homeostasis (18, 19) . The possible production (2) and presence of AM-like immunoreactivity (3, 4, 6) in brain and pituitary gland have been reported, and immunohistochemical studies have localized AM immunoreactivity to neurons of the hypothalamo-neurohypohysial tract where the peptide is colocalized with oxytocin and vasopressin (29) . It is not known whether circulating AM can cross the blood-brain barrier; however, it may gain access to the neuropil in circumventricular organs such as the subfornical organ or organum vasculosum lamina terminalis, where the barrier is absent. Alternatively, locally synthesized AM may act in a paracrine or neurocrine fashion within the brain. Receptors selective for AM have been identified in several brain sites, including those known to be important in the control of cardiovascular and renal function (20) . Central administration of doses of AM that failed to alter blood pressure or heart rate significantly inhibited water drinking in response to pharmacological (angiotensin II injection) and physiological (overnight water deprivation) stimuli (19) . That was the first report to suggest direct neural actions of AM in conscious animals. Although we did not observe effects on sympathetic outflow after lateral ventricular administration using doses of AM that were active in the behavioral paradigm (250 and 500 ng/rat), one group using higher doses of the peptide (ϳ4.5-5.0 g/rat) did observe stimulatory effects that were delayed in onset (suggesting a distant site of action) and sustained (27) . When we raised the doses of AM to levels 2-and 4-fold greater than those employed in our drinking studies (to 1.0 and 2.0 g) again no significant effects on blood pressure or heart rate were observed (19) . Thus, we were able to dissociate the waterdrinking effects from potential alterations in sympathetic function.
It is possible that by injecting the peptide into the lateral cerebroventricle we were not applying sufficient peptide to reach a site more distant than the rostral diencephalon, whereas the other group whose injection volumes and doses were greater (27) did apply sufficient peptide to diffuse to more distant sites of action. Indeed, the delay in onset of action suggests that in their studies a more downstream site, such as the region of the fourth cerebral ventricle, was the target site. This hypothesis had been supported by the single unit recording studies in the rat which demonstrated significant direct neural effects of AM in the area postrema and nucleus tractus solitarius (28) . Although the doses employed by Allen and Ferguson (28) in those recording studies (ϳ5-500 ng/ml) were similar to the total in vivo doses we employed (250 and 500 ng/rat), these may result in pharmacological exposure of the tissue to exogenous AM. It is difficult to extrapolate the exact amount of endogenous AM in distinct brain regions of the rat because published reports detail the data in terms of moles of AM per g wet tissue wt (3) and do not detail the weights of tissues collected for extraction. In all likelihood, the level of endogenous peptide is in the picogram to nanogram range in hypothalamus and brain stem, like other vasoactive peptides found in brain (30) . Thus, our peptide injections may not be in the physiological range. However, the doses employed here are similar to those used in earlier studies to uncover the apparent physiological roles of oxytocin (21) and atrial natriuretic peptide (31) in the central nervous system control of sodium homeostasis, and as in those studies, administration of agents that compromise the actions of those peptides, in this case anti-AM antiserum, uncovers a potential physiological relevance of endogenous peptide. It should be noted that al- though the salt-satiating effect of AM is similar to that of oxytocin and atrial natriuretic peptide (31), the anti-AM antiserum employed does not recognize those peptides even when tested in a 4 log molar excess. Finally, administration of peptides into the ventricular system for delivery to distant brain sites along the cavity as well as within the interstitium introduces a dilution artifact that makes it impossible to extrapolate from nanograms administered to the actual amount eventually accessing the synaptic cleft where biological action may occur. Just how AM acts at the cellular level is unclear. It may interact with oxytocinergic neural elements or modulate the release of endogenous ANP. Alternatively, AM may act, as it does in peripheral tissues, directly to activate nitric oxide production or adenylate cyclase activity. It would be difficult if not impossible to identify single unique cellular mechanisms with in vivo models, and as we have done in pituitary cell culture (18) , in vitro studies are now underway addressing the issue of second messenger recruitment by AM.
The data reported here further suggest direct central nervous system actions of AM to interact with brain mechanisms regulating fluid and electrolyte homeostasis. The ability of intracerebroventricular administration of AM to inhibit salt appetite in the rat may be a central action that mirrors the natriuretic effects of the peptide in the kidney and the adrenal effects to inhibit aldosterone secretion. When considered along with the peptide's ability to inhibit water drinking in other paradigms (19) and to act within the pituitary gland to inhibit basal and stimulated ACTH secretion (18) , this effect of AM on salt appetite may represent a physiologically relevant action by which the peptide controls cardiovascular and renal function. The data from the passive immunoneutralization study further suggest that endogenous AM plays a potentially physiological role in the central regulation of sodium homeostasis. Indeed, in this model of isotonic hypovolemia, the rats administered AM or in which endogenous AM may have been neutralized by antibodies appeared to be able to appropriately replace volume, but not in the process balance tonicity. Thus, a major function of AM in the brain may be, as in the periphery, not only to assure normal volume status, but also to maintain appropriate plasma sodium levels and osmolarity.
